Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 10/20 | 0.92 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.92 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.92 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249763 | 0.98 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL5852136 | 0.98 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL19779489 | 0.98 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Dimethylamine SCHEMBL6943083 | 0.94 | GNAO1 (0.82) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL6941884 | 0.93 | GNAO1 (0.81) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Hydrochloric Acid SCHEMBL9481013 | 0.91 | GNAO1 (0.85) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| Diethylamine SCHEMBL6941583 | 0.91 | GNAO1 (0.77) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL7078379 | 0.89 | GNAO1 (0.74) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL7227721 | 0.89 | GNAO1 (0.74) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL6942008 | 0.89 | GNAO1 (0.74) | GNAO1GNAI3GNAI1SPHK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019013789-A1 | ANTIMICROBIAL COMPOUNDS | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019013790-A1 | ANTIMICROBIAL COMPOUNDS AND USES THEREOF | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| CN-108135175-A | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-2089384-B1 | 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| US-7998969-B2 | enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases | ROCHE PALO ALTO LLC (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-4208418-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-06-17 | — | — | US | disclosed |
| US-4198411-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-15 | — | — | US | disclosed |
| US-4197303-A | ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4197304-A | ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4196210-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-01 | — | — | US | disclosed |
| US-4157393-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-06-05 | — | — | US | disclosed |
| US-4151286-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-04-24 | — | — | US | disclosed |
| US-4148783-A | HEAT, LIGHT, OXIDATION, AGING RESISTANCE, STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148783-A | HEAT, LIGHT, OXIDATION, AGING RESISTANCE, STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1979-04-10 | — | — | US | disclosed |
| US-4126689-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | GNAO1 1000/4885GNAI3 847/4885GNAI1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.